December 10, 2019

SAN DIEGO, California, USA, December 10, 2019 -- SAN DIEGO - Cullgen Inc., a biotechnology company developing small molecule therapeutics based on targeted protein degradation technology (commonly known as PROTAC), today announced that Dr. Jian Jin, a co-founder of Cullgen, has designed a novel targeted protein degrader that may be able to stop the growth of triple-negative breast cancer, a type of breast cancer for which there are few viable treatment options, according to a study recently published in Nature Chemical Biology entitled “Discovery of a first-in-class EZH2 selective degrader”. The complete publication can be found online here: https://www.nature.com/articles/s41589-019-0421-4

About Cullgen Inc.

Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our proprietary technology platform, ubiquitin-mediated, small molecule-induced target elimination technology, (uSMITE™), based on recent advances in the science of protein degradation. Typically, drugs are designed to interact with the functional sites of proteins and block their activities. We are developing uSMITE™ to expand the drug design paradigm beyond functional site inhibition, to make it possible to eliminate previously “undruggable” enzymes and proteins by targeted destruction. We also intend to use the uSMITE™ technology to harness the ubiquitin proteasome system, a multi-step biochemical process that controls protein degradation in all cells. From years of research on the proteasome system and key discoveries about its assembly, Cullgen’s founders have already demonstrated that the underlying technology can rapidly generate a large number of highly potent, selective, and bioavailable compounds. Furthermore, this process is significantly more cost effective compared with traditional drug discovery approaches. For more information, visit www.cullgen.com.

Contacts

Cullgen Inc.

+1 858-284-0115

inquiries@cullgen.com